Chapter 40 Clinical Approach to Infections in the Compromised Host
Figure 40-1 CONSTELLATION OF FACTORS CONTRIBUTING TO INCREASED RISK FOR INFECTION IN IMMUNOCOMPROMISED HOSTS.
Hematologic Condition | Infection-Predisposing Host Defects |
---|---|
Acute myeloid leukemia | Neutropenia; therapies such as dose-intensive chemotherapy and hematopoietic stem cell transplant may result in additional anatomic disruptions, cell-mediated defects, and humoral defects |
Acute lymphocytic leukemia | Neutropenia; therapy effects similar to acute myeloid leukemia |
Hairy cell leukemia | Neutropenia (also monocytopenia); abnormal humoral immunity; T-cell suppressing therapy |
Chronic lymphocytic leukemia | Hypogammaglobulinemia; abnormal cell-mediated immunity |
Chronic myeloid leukemia | No prominent host defects unless aggressive therapy, advanced stage, or postsplenectomy |
Multiple myeloma | Hypogammaglobulinemia; other host defects may occur with aggressive therapy or advanced stage |
Hodgkin/non-Hodgkin lymphomas | Abnormal cell-mediated immunity, therapy-related neutropenia, splenic dysfunction (if splenectomy or radiation) |
Myelodysplastic syndromes | Functional or absolute neutropenia |
Aplastic anemia | Neutropenia; abnormal cell-mediated immunity from immunosuppressive therapies (e.g., steroids, antithymocyte globulin, cyclosporine, hematopoietic stem cell transplantation) |
Paroxysmal nocturnal hemoglobinuria | Deficient Fc receptor may contribute to abnormal cell-mediated immunity |
Hemolytic states (thalassemia) | Gallstones may serve as a nidus for infection; splenic dysfunction or splenectomy |
Sickle cell disease | Can be neutropenic with aplastic crisis; bone infarcts may serve as a nidus for infection; splenic dysfunction with poor complement activation and opsonization from autosplenectomy |